Foxx Development (NASDAQ:FOXX) CTO James Liao Sells 1,943 Shares

Foxx Development Holdings Inc. (NASDAQ:FOXX) CTO James Liao sold 1,943 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $6.15, for a total transaction of $11,949.45. Following the transaction, the chief technology officer owned 19,431 shares in the company, valued at approximately $119,500.65. The trade was a 9.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Foxx Development Trading Down 3.6%

FOXX opened at $5.06 on Friday. The company’s fifty day moving average price is $4.70 and its two-hundred day moving average price is $4.52. Foxx Development Holdings Inc. has a 1-year low of $1.71 and a 1-year high of $8.88. The company has a market cap of $35.62 million, a price-to-earnings ratio of -0.74 and a beta of -0.31.

Foxx Development (NASDAQ:FOXX) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($5.19) earnings per share for the quarter. The business had revenue of $8.67 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Foxx Development from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Foxx Development presently has an average rating of “Sell”.

Institutional Trading of Foxx Development

A hedge fund recently bought a new stake in Foxx Development stock. Citadel Advisors LLC purchased a new stake in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 12,025 shares of the company’s stock, valued at approximately $57,000. Citadel Advisors LLC owned 0.18% of Foxx Development as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 60.44% of the company’s stock.

Foxx Development Company Profile

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.